About AKLIEF® (trifarotene) Cream, 0.005%:

THE FIRST NEW RETINOID MOLECULE FOR THE TREATMENT OF ACNE IN 20 YEARS.1

THE FIRST TOPICAL TREATMENT WITH PROVEN RESULTS IN TREATING FACIAL AND TRUNCAL ACNE IS HERE.1,2

AKLIEF Cream is a new retinoid proven to provide potent and selective activity at the most common retinoic acid receptor (RAR) found in the skin, RAR-γ, allowing it to be effective at low doses. AKLIEF Cream was designed to make it suitable for use across large treatment areas.2 Furthermore, it is expected to be rapidly eliminated from the body, resulting in low systemic exposure.2-4

Image

AKLIEF Cream in action THE POWER OF PRECISION.

The first topical retinoid to specifically target RAR-γ, the most prevalent receptor in the skin.2,3

WATCH NOW

PROVEN EFFICACY IN TREATING
ACNE VULGARIS IN

2,000+

PATIENTS ENROLLED IN 2 CLINICAL TRIALS1

RAPID RESULTS.* POWERFUL EFFICACY. EXCELLENT TOLERABILITY.1

View Clinical Data

*Indicating a 2-week time frame until results on the face; a 4-week time frame until results on the trunk.1

ACNE THAT'S BEYOND WHAT'S IN PLAIN SIGHT.

Patients with truncal acne may not freely talk about it with their doctors for various reasons. However, if left untreated, it can have a negative impact of their daily lives.5,6

LEARN MORE

References: 1. AKLIEF Press Release. Federal Drug Administration approval 2019. 2. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 µg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699. 3. Fisher GJ, Talwar HS, Xiao J-H, et al. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem. 1994;269(32):20629-20635. 4. Aubert J, Piwnica D, Bertino D, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol. 2018;179(2):442-456. 5. Mandy SH. Chest and back acne: A retrospective review. Adv Ther. 1995;12(6):321-332. 6. Del Rosso JQ, Bikowski, JB, Baum E, et al. A closer look at truncal acne vulgaris: Prevalence, severity, and clinical significance. J Drugs Dermatol. 2007;6:597-600.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Please see full Important Safety Information below.

Scroll to ISI